Pralidoxime (2-PAM)

Mechanism

Pharmacological Group and Molecular Target

Enzymatic reactivator of the high affinity nucleophilic oxime family.

Detailed Mechanism of Action

Organophosphate insecticides inactivate acetylcholinesterase (AChE) by phosphorylating the serine residue at its catalytic site. This strong covalent bond undergoes a time-dependent chemical dealkylation process known as "aging" of the enzyme, which is irreversible once completed. (aging) of the enzyme, which becomes irreversible once complete.

Pralidoxime has a positively charged quaternary ammonium nitrogen that binds electrostatically to the free anionic site of phosphorylated cholinesterase. Its nucleophilic oxime group attacks the organophosphate phosphorus atom, cleaving the phosphorus–serine ester bond, forming an inactive oxime–organophosphate conjugate and restoring the catalytic activity of functional free AChE enzyme.

Critical Time Window Before Enzyme Aging

Enzymatic reactivation by oximes is clinically futile once the enzyme has undergone biochemical aging. The aging half-life varies drastically depending on the chemical structure of the offending organophosphate compound:

Soman (nerve agent): Ages within 2 to 6 minutes (Oximes ineffective unless administered immediately) Dimethoate (insecticide): Ages within 12 to 24 hours (Moderate therapeutic window) Chlorpyrifos or Methyl parathion: Ages within 30 to 48 hours (Extended therapeutic window)

Pharmacokinetics

Pharmacokinetic and Toxicokinetic Profile

• Distribution: It does not bind significantly to plasma proteins. Being a hydrophilic quaternary ammonium compound, it does not easily cross the blood-brain barrier under normal conditions, therefore it lacks a direct effect on central nervous system (CNS) cholinergic toxicity compared to its potent effect on peripheral nicotinic receptors at the neuromuscular junction.
• Metabolism: Minimal hepatic.
• Excretion: Renal; 80% is excreted unchanged in the urine in the first 6 hours by active tubular secretion and glomerular filtration.
• Elimination half-life: Short, between 1 and 1.5 hours.

Indicators and dose

Specific Clinical Indications

• Treatment of toxicity by organophosphate pesticides and cholinesterase-related inhibitors, in obligatory combination with atropine.
• Treatment of profound neuromuscular weakness and paralysis of respiratory muscles (Intermediate Syndrome) associated with organophosphates.

Dosage Scheme and Infusion Protocols

• Loading Dose (Adults): 1 g to 2 g administered IV diluted in 100 mL of 0.9% normal saline to infuse over a period of 15 to 30 minutes. An excessively rapid infusion can cause neuromuscular rigidity, reflex tachycardia, and severe hypertension.
• Maintenance Dose: Continuous intravenous infusion of 500 mg/hour to avoid a sudden drop in effective therapeutic concentrations (maintenance of plasma levels greater than 4 mg/L).
• Kidney adjustment: In proven renal failure (eGFR <30 mL/min), the continuous infusion rate should be reduced by half (50%) to avoid plasma accumulation.

Security

Contraindications and Precautions

• Absolute Contraindication: Pure poisoning by carbamate insecticides (such as Carbaril), given that enzymatic carbamylation is transient and self-limiting, and the use of pralidoxime can increase the affinity of the toxin for the synaptic receptor, worsening neuromuscular symptoms (with the exception of combined or aldicarb poisoning).